It's the year of the spinoff in health care, with a variety of new businesses making their market debuts so far in 2013, and at least one more is planned for later in the year.
In the following video, health care bureau chief Brenton Flynn outlines the separation of AbbVie and Zoetis from Abbott Labs and Pfizer , respectively, and explains to investors both the rationale for the moves and whether they've added value so far for shareholders.
Should you sell Abbott or AbbVie?
In order to answer that question, you have to understand what each company has to offer investors. To help you better understand the situation, we've composed premium research reports on both companies. By picking up a copy of our Abbott Labs report, for a limited time only you'll receive a FREE glimpse into our new report on AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this report by clicking here now.
The article Did AbbVie and Zoetis Add Value for Abbott Labs and Pfizer Shareholders? originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.